Tumor-activated Engagers (VY-GAGE)

Precision Immunotherapy Designed to Overcome Cancer’s Defense Mechanisms

Vycellix is positioned to establish a new leading class of cancer killing multi-antigen engagers with precision tumor-activated delivery, avoiding “on-target, off-tumor” adverse effects (VY-GAGE).

VY-GAGE is a novel therapeutic capable of delivering multiple-disease-targeting payloads directly to tumor sites, including deploying potent BiKEs (bispecific killer cell engagers) and CARs (chimeric antigen receptors).  Vycellix is developing highly targeted, highly specific cell therapies that can deliver high doses of disease-targeting agents, which are believed to be safer and more effective by limiting cytotoxic killing to only occur within the solid tumor microenvironment.

Consolidates multi-modal immunotherapies into a single tumor-directed therapy